Palovarotene (Sohonos; Ipsen Biopharmaceuticals Inc.) is an oral retinoid indicated for the reduction in volume of new heterotopic ossification in adults and pediatric patients aged 8 years and older for female persons and 10 years and older for male persons with fibrodysplasia ossificans progressiva.
